PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
14523625-2	2003	TH-, MAP 2- and DAT-immunoreactive cells were decreased gradually in the striatum and substantia nigra from 1 day up to 7 days after MPTP treatment, as well as the reduction of the striatal dopamine, DOPAC and HVA content.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	133-137	microtubule-associated protein 2	Mus musculus	5-10	
11578843-6	2001	MPTP treatment also caused a severe decrease in the amount of nigral tyrosine hydroxylase protein (TH) and microtuble-associated protein 2 (MAP 2) and produced a marked increase in the striatal glial fibrillary acidic protein (GFAP).	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	0-4	microtubule-associated protein 2	Mus musculus	107-138	
11578843-6	2001	MPTP treatment also caused a severe decrease in the amount of nigral tyrosine hydroxylase protein (TH) and microtuble-associated protein 2 (MAP 2) and produced a marked increase in the striatal glial fibrillary acidic protein (GFAP).	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	0-4	microtubule-associated protein 2	Mus musculus	140-145	
23558233-10	2013	Three transcripts representing Mtap2, Lancl 1, and Kansl1l were highly correlated with the PC, as was the difference score, MPTP minus saline for GFAP.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	124-128	microtubule-associated protein 2	Mus musculus	31-36	
11578843-7	2001	Our immunohistochemical study with TH and MAP 2 staining showed that riluzole can protect against MPTP-induced neuronal damage in the substantia nigra.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	98-102	microtubule-associated protein 2	Mus musculus	42-47